Inventiva S.A.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVA research report →
Companywww.inventivapharma.com
Inventiva S. A. , a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases.
- CEO
- Andrew Obenshain
- IPO
- 2020
- Employees
- 114
- HQ
- Daix, FR
Price Chart
Valuation
- Market Cap
- $267.19M
- P/E
- -7.97
- P/S
- 137.42
- P/B
- -98.95
- EV/EBITDA
- -4.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 35.07%
- Op Margin
- -3037.30%
- Net Margin
- -7899.58%
- ROE
- 1870.38%
- ROIC
- -66.18%
Growth & Income
- Revenue
- $4.48M · -51.26%
- Net Income
- $-340,161,126 · -84.66%
- EPS
- $-1.82 · 48.59%
- Op Income
- $-130,946,540
- FCF YoY
- -17.34%
Performance & Tape
- 52W High
- $7.98
- 52W Low
- $2.85
- 50D MA
- $5.57
- 200D MA
- $5.28
- Beta
- 0.88
- Avg Volume
- 338.84K
Get TickerSpark's AI analysis on IVA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IVA Coverage
We haven't published any research on IVA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IVA Report →